Autonomix Medical, Inc. (AMIX) · Nov 3, 2026 · Other events

Autonomix Medical approves reverse-split authority and adds shares

Annual meeting approvals — 750,000 additional plan shares; 1-for-2 to 1-for-25 reverse-split authority

Autonomix Medical’s annual meeting approved reverse-split authority and expanded its stock plan, preserving flexibility but adding no immediate operating catalyst.

Autonomix is still a development-stage medical-device company building a catheter-based sensing and nerve-ablation platform, initially targeting pancreatic-cancer pain; it had already completed a 1-for-21 reverse split on June 24, 2026 as part of its listing strategy.

The vote preserves financing and listing flexibility, but does not advance the medical-device program. Stockholders approved a 750,000-share increase to the 2023 Stock Plan, bringing the plan’s authorized shares to 750,353. 〔0〕 That gives Autonomix more room for equity compensation, but it also expands potential dilution in a company with only 1,959,938 shares outstanding as of the record date.

The reverse-split authorization is defensive optionality, not an executed transaction. Investors approved Board authority to implement a 1-for-2 to 1-for-25 reverse split within one year, but the filing does not say that a split has been scheduled or will occur. 〔1〕

The outcome was largely known before the filing. These proposals were laid out in the September 14, 2026 proxy, and the company says all director nominees and other submitted matters were approved. 〔2〕 With roughly 46% of shares voting, the annual meeting confirms the planned governance and capital actions but adds no new clinical, commercial, or funding information.

Bottom line: This is a confirmation of previously disclosed capital-management tools: more equity-plan capacity and the ability to reverse split if needed. It preserves flexibility but leaves Autonomix’s core development story unchanged and carries no genuine surprise for the market.

What to watch next

Board decision on whether to execute a reverse split

Original filing on SEC EDGAR